Serum C3 levels in acute glomerulonephritis

Serum C3 levels in acute glomerulonephritis and postnephritic children.

C3 glomerulonephritis in multiple myeloma

BACKGROUND C3 glomerulonephritis (C3 GN) is a recently defined entity characterized by predominant C3 deposition in glomeruli due to abnormal activation of the alternative pathway of complement system. C3 GN has been reported to be associated with several systemic diseases. However, the association between C3 GN and multiple myeloma (MM) has not been well established. METHODS We herein descri...

The Serum Antistreptolysin Titer in Acute Glomerulonephritis.

This work on the level of an'tistreptolysin titer in the serum of patients with acute glomerulonephritis is part of a study being conducted by the Departments of Medicine and Pediatrics on the role of infection in acute and chronic glomerulonephritis. The literature and texts list the most heterogeneous types of infection (influenza, diphtheria, measles, the common cold, sore throat, exposure, ...

Serum complement (C3, C4) levels in patients with acute myocardial infarction and angina pectoris.

Serum complement (C3, C4) levels in Libyan patients with acute myocardial infarction (AMI; 31 patients) and angina pectoris (AP; 11 patients) at the 1st day and 7th day of attack were estimated. A group of 26 healthy Libyans were taken as control subjects (CS). Serum C3 and C4 levels (mean +/- SD, mg/dl) were elevated at the 1st day in AMI as well as AP patients (C3 --> AMI1: 154.0 +/- 28.5, AP...

Timing of eculizumab therapy for C3 glomerulonephritis

Eculizumab is an anti-C5 antibody that inhibits C5 cleavage and prevents the generation of the terminal complement complex C5b-9. Eculizumab is licensed to treat paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome (aHUS). Clinical trials are ongoing for C3 glomerulopathy. Given the unfamiliarity of physicians with these rare diseases and the variability of clinical pres...